Breast Cancer Clinical Trial
Official title:
Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | September 1, 2031 |
Est. primary completion date | September 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Willingness and ability to sign and date the study-specific informed consent form. - Stated willingness to comply with all study procedures and attend all study visits to the best of his or her ability for the duration of the study. - Age greater than 18yo. - Stage I-III TNBC or stage IV TNBC with intact breast primary. - Planned combined ICI therapy as per SoC by treating oncologist. Exclusion Criteria: - Other clinical trials are not excluded but participation must be cleared with the other clinical trial PIs. - Patients not suitable to undergo contrast enhanced ultrasound (i.e., pregnant women, known allergy to eggs, or a past allergic reaction to sonographic contrast or its components, such as polyethylene glycol (PEG)) |
Country | Name | City | State |
---|---|---|---|
United States | Penn State Health College of Medicine | Hershey | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Milton S. Hershey Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Volume of mass on as visualized on contrast (Lumason) enhanced ultrasound at Baseline | Day 0 (Baseline) | ||
Primary | Volume of mass on as visualized on contrast (Lumason) enhanced ultrasound at C2 | No later than week 5 | ||
Primary | Volume of mass on as visualized on contrast (Lumason) enhanced ultrasound at C3 | No later than week 9 | ||
Primary | Volume of mass on as visualized on contrast (Lumason) enhanced ultrasound at C4 | No later than week 13 | ||
Primary | Contrast (Lumason) enhanced ultrasound metric-area under the curve-at Baseline | Day 0 (Baseline) | ||
Primary | Contrast (Lumason) enhanced ultrasound metric-area under the curve-at C2 | No later than week 5 | ||
Primary | Contrast (Lumason) enhanced ultrasound metric-area under the curve-at C3 | No later than week 9 | ||
Primary | Contrast (Lumason) enhanced ultrasound metric-area under the curve-at C4 | No later than week 13 | ||
Primary | Number of subjects who respond to treatment as reported on routine imaging. | No later than week 17 | ||
Secondary | Change in area under the curve (CEUS metric) between Baseline & C2 | No later than year 5 | ||
Secondary | Change in area under the curve (CEUS metric) between Baseline & C3 | No later than year 5 | ||
Secondary | Change in area under the curve (CEUS metric) between Baseline & C4 | No later than year 5 | ||
Secondary | Change in area under the curve (CEUS metric) between C2 & C3 | No later than year 5 | ||
Secondary | Change in area under the curve (CEUS metric) between C2 & C4 | No later than year 5 | ||
Secondary | Change in area under the curve (CEUS metric) between C3 & C4 | No later than year 5 | ||
Secondary | Number of subjects having pathologic complete response | No later than year 5 | ||
Secondary | Overall survival (time to subject death) | No later than year 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |